We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions

By LabMedica International staff writers
Posted on 14 Aug 2023
Print article
Image: A new study has linked part of CBC with risk of hospital admission and in-hospital mortality (Photo courtesy of Shutterstock)
Image: A new study has linked part of CBC with risk of hospital admission and in-hospital mortality (Photo courtesy of Shutterstock)

Red blood cell distribution width (RDW), an integral component of the complete blood count (CBC) panel, measures the variation in red blood cell size. Increased RDW levels have demonstrated a relation to unfavorable patient outcomes across a range of diseases, spanning from heart attacks to COVID-19 pneumonia. Recent research has identified RDW as a generalizable biomarker for emergency department (ED) acuity. However, there have been few studies to examine the prognostic value of RDW within the ED setting. Previous studies have mainly focused on specific diseases like acute coronary syndrome, deep vein thrombosis, and sepsis, often employing limited sample sizes ranging from hundreds to thousands of patients. Now, a new study using a large dataset of ED visits has revealed that higher RDW value in the ED is correlated to hospital admission and, in individuals admitted to the hospital, in-hospital mortality.

Researchers in the Department of Emergency Medicine at UCLA David Geffen School of Medicine (Los Angeles, CA, USA) conducted a retrospective analysis of over 200,000 adult ED visits with CBC results between the period March 2013 and February 2022. The study’s key objective was to investigate the correlation between initial RDW measurements obtained during ED visits and two crucial outcomes: hospital admission and in-hospital mortality. The study revealed that elevated RDW levels were notably prevalent in visits culminating in hospital admission. Moreover, among admitted patients, those necessitating intensive care unit (ICU) care or experiencing in-hospital mortality exhibited even higher RDW values.

An RDW value of more than 16 demonstrated a specificity of 90% for predicting hospital admission, while an RDW value exceeding 18.5 demonstrated 90% specificity for predicting in-hospital mortality. These findings are in line with prior studies that have linked heightened RDW levels to higher mortality risks in conditions such as myocardial infarction, pulmonary embolism, heart failure, sepsis, and COVID-19. However, the latest study establishes a relation between RDW and overall hospital admissions as well as in-hospital mortality across all-cause adult ED visits. According to the researchers, while elevated RDW alone might not possess the sensitivity required for a comprehensive diagnostic tool, combining it with other clinical data could substantially enhance clinicians' capacity to predict hospital admissions and identify patients at heightened risk of in-hospital mortality.

Related Links:
UCLA David Geffen School of Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.